It is a new investigational drug, created for the treatment of multiple sclerosis (a disease that causes injury to the brain, spinal cord and neurological deterioration) which has had very good results in people who have been treated with it., since it significantly reduces the progression of disability.
Ocrelizumab is being designed to selectively attack the CD20B protein, which has a kind of immunity and is believed to play an important role in the deterioration of myelin and nerves, which is a common trait in patients with sclerosis. multiple, the drug acts by binding to the surface of said protein, thus preserving the most important functions of the immune system.
This drug received approval from the American Drug Agency by showing great results in phase III, where it was proven to have had better results compared to a placebo, greatly reducing the progression of disability, according to experts from Hospital Vall d 'Hebron from Barcelona who have been in charge of leading the investigation, the drug delays the progression of the disease in its initial phase by at least 12 weeks. In this experiment 732 patients participated with primary progressive multiple sclerosis and shown to be decreased by 24% the progression and 120 weeks have elapsed time required for the walk was decreased by 29% amountof brain injuries improved by 3.4% and the loss of brain volume decreased by 17.5%.
This disease affects around 2.5 million people around the world and occurs when the immune system abnormally attacks myelin, causing damage to the brain and spinal cord, this in turn affects the optic nerve, causing, weakness, fatigue, and difficulty seeing, which can become more serious over time.
Until now, multiple sclerosis has no cure, therefore, patients suffering from this disability lack any available treatment, which is why ocrelizumab, despite being still in the experimental phase, has given good results, being a great hopeful advance for those affected and the science itself.
